Cullinan Oncology(CGEM) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results Global Phase 1 study of CLN-978 in systemic lupus erythematosus (SLE) cleared to initiate in U.S. and Australia; initial clinical data expected in Q4 2025 CLN-619 on-track for initial expansion cohort data in endometrial and cervical cancers in Q2 2025 Zipalertinib pivotal Phase 2b study enrollment completed ahead of schedule; results expected midyear 2025 CAMBRIDGE, Mass. November 7, 2024 (GLOBE NE ...